Novel coronavirus vaccine based on chimeric virus-like particles

A virus and chimeric protein technology, applied in the field of human vaccines and human biological products, can solve the problem of no clear drug application for COVID-19, and achieve good immune effect, enhanced immune response, and good immune protection.

Pending Publication Date: 2020-09-04
SUZHOU MIDI BIOTECH CO LTD
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for combining different parts from viruses like bacteria called Hepatoid Adeno Virus or other similar microorganisms into one particle called an infectious agent made up mostly of DNA. These agents are then used to attack cells inside these organism's body through their own mechanism - they make them stronger against another type of disease caused by this virus.

Problems solved by technology

This patented technical problem addressed in this patents relates to finding effective treatments or prophylaxis methods for virally related conditions such as CO VIDES due to its ability to block certain types of microorganisms like other strains causing harmful effects during their spread across different regions worldwide.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel coronavirus vaccine based on chimeric virus-like particles
  • Novel coronavirus vaccine based on chimeric virus-like particles
  • Novel coronavirus vaccine based on chimeric virus-like particles

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0041] Another aspect of the embodiments of the present invention also provides a method for preparing the chimeric virus-like particle, which includes: transforming the recombinant vector containing the coding gene into Escherichia coli, and then culturing and post-processing to obtain The chimeric virus-like particle. The post-treatment includes operations such as cell lysis and protein purification, which are well known to those skilled in the art.

[0042] In the above embodiments of the present invention, the receptor binding region (S RBD , at least part of the sequence is shown in SEQ ID NO: 4) chimerized to the MIR region of HBcAg (at least part of the sequence is shown in SEQ ID NO: 3, wherein the 1-143rd is the assembly domain, and the 150-183rd It is the C-terminal domain CTD), which can be formed in the virus-like particles (hereinafter also referred to as S RBD / HBcAg chimeric virus-like particles) display the receptor-binding region of S protein on the surface,...

Embodiment 1

[0047] The construction of embodiment 1 recombinant escherichia coli

[0048] The codon-optimized S was synthesized at Shanghai Sunny Biotechnology Co., Ltd. RBD / HBcAg gene (SEQ ID NO: 1), inserted between NdeI / XhoI of pET-22b(+), to obtain recombinant pET-22b-S RBD / HBcAg plasmid, transform this plasmid into Escherichia coli, spread it on LB-1% agarose-amp+semi-solid medium plate and culture overnight, and the resulting clone expresses S RBD coli / HBcAg chimeric antigen.

Embodiment 2

[0049] Example 2 Recombinant S RBD Preparation of HBcAg Chimeric Antigen Virus-Like Particles

[0050] 1. Pick the obtained recombinant Escherichia coli in Example 1 and cultivate it in LB medium, the culture temperature is 16°C, when the OD 600 When the value reaches 0.8, add IPTG to a final concentration of 0.1mM. After 16 hours, stop the fermentation, harvest the cells, centrifuge at 8000rpm for 15 minutes at 4°C, harvest the cells, and freeze them at -20°C until use;

[0051] 2. Resuspend Escherichia coli in 50mM Tris pH 7.5, 5mM DTT solution according to 1:4 (w:v), and add protease inhibitors, DNase 0.01mg / mL and RNase A 0.1mg / mL;

[0052] 3. Sonicate the cells in an ice bath for 15s, pause for 15s, and continue for 1min, repeating this 7-10 times;

[0053] Centrifuge at 4.4°C and 27000g for 30min, and harvest the supernatant;

[0054] 5. Slowly add ammonium sulfate to the harvested supernatant to 40% saturation, which is equivalent to a concentration of 30% (w / v), and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a novel coronavirus vaccine based on chimeric virus-like particles, and the vaccine contains chimeric virus-like particles as effective ingredients. The chimeric virus-like particles are mainly formed by the aggregation of a type of recombinant chimeric proteins, and the recombinant chimeric proteins are obtained by fusing the S protein receptor binding region of SARS-CoV-2virus into the major immune determining region of HBcAg. The vaccine of the present invention can produce a strong immune response in human bodies, and humans can resist new coronavirus infections after immunization.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner SUZHOU MIDI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap